Relief Therapeutics

Welcome to

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Relief is a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis.

Relief Therapeutics Announces Executive Leadership Team Changes

8 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

16 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

14 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

8 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

7 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement

26 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

25 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

14 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Announces U.S. Launch of PKU GOLIKE

10 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

6 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Latest News

Relief Therapeutics Announces Executive Leadership Team Changes

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

Relief Announces U.S. Launch of PKU GOLIKE

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

Company

Pipeline

Investor Relations

News and Events